98th Annual Meeting of the American Association for Cancer Research
TORONTO, April 17 /CNW/ - Lorus Therapeutics Inc. ("Lorus") (TSX: LOR;
AMEX: LRP) today announced presentation of research on their lead antisense
and siRNA compounds at the 98th Annual Meeting of the AACR in Los Angeles, CA,
April 14-18, 2007.
The first presentation titled, "Determination of optimized administration
schedule of GTI-2040 and docetaxel combination treatment for NSCLC cells in
vitro and in vivo," was presented on April 15, 2007.
This research determined a new optimal dosing schedule of GTI-2040 and
docetaxel, which resulted in greatly enhanced synergy when docetaxel was given
48 hours after GTI-2040 compared to concomitant administration. This strong
synergy was seen in vivo even after a single dose of GTI-2040. The discovery
that administration of GTI-2040 prior to docetaxel is associated with this
synergy, possibly through a 'stressor' effect due to decreased levels of R2
target expression, may potentially apply to other GTI-2040 combinations as
well. This new sequential dose strategy will be an important consideration to
maximize efficacy in the GTI-2040 clinical program.
The second presentation titled, "siRNAs targeting the R2 subunit of human
ribonucleotide reductase exhibit in vitro and in vivo antitumor activity,"
will be presented on April 17, 2007.
In this research, Lorus screened a series of siRNAs to select a lead drug
candidate, siRNA-1284. siRNA-1284 demonstrated potent antiproliferative and
antitumor activity both in vitro and in vivo, coinciding with specific target
silencing. These data warrant further development of siRNA-1284 as an
anticancer agent. Lorus is also pursuing other cancer targets with its siRNA
platform technology to screen and evaluate novel siRNA drug candidates.
"The research announced today provides important supporting data for
Lorus' drug development strategies involving antisense and siRNA," commented
Dr. Aiping Young, Lorus' President and CEO. "The novel findings involving
GTI-2040 combined with docetaxel provide an important new approach for
optimizing combination therapies with GTI-2040, which may be particularly
relevant to future GTI-2040 trials in solid tumor indications. We are also
very pleased with the identification of our lead siRNA drug, adding to our
growing platform of DNA/RNA-based medicines."
GTI-2040 is an antisense drug that specifically targets the R2 component
of ribonucleotide reductase, which is required for DNA synthesis and cell
proliferation. R2 has also been described as a malignant determinant that is
elevated in a wide range of tumors, and through down regulation can cooperate
with a variety of cellular cancer causing genes known as oncogenes to enhance
tumor growth and metastatic potential.
siRNA is a novel class of molecules that can decrease cellular target RNA
expression through an antisense process known as RNA interference (RNAi).
Because of its target specificity, RNAi is increasingly being examined as a
potential therapy for a variety of diseases including cancer. From an
evolutionary perspective, RNAi helps protect cells from viruses and
transposable genetic elements in addition to carrying out more routine
cellular tasks essential to development and growth. In mammalian cells siRNAs
have been shown to be the most effective tools for RNAi, allowing for the
development of clean and easily regulated methods for disruption of gene
expression. siRNA technology allows for a range of new applications including
target validation for drug discovery and medical therapeutics.
Lorus is a biopharmaceutical company focused on the research and
development of novel therapeutics in cancer. Lorus' goal is to capitalize on
its research, preclinical, clinical and regulatory expertise by developing new
drug candidates that can be used, either alone, or in combination with other
drugs, to successfully manage cancer. Through its own discovery efforts and an
acquisition and in-licensing program, Lorus is building a portfolio of
promising anticancer drugs. Lorus has several product candidates in multiple
Phase II clinical trials and has completed one Phase II and one Phase III
clinical trial. Lorus Therapeutics Inc. is listed on the Toronto Stock
Exchange under the symbol LOR, and on the American Stock Exchange under the
Forward looking statements
This press release may contain forward-looking statements within the
meaning of Canadian and U.S. securities laws. Such statements include, but are
not limited to, statements relating to: our research program plans, our plans
to conduct clinical trials, the successful and timely completion of clinical
studies and the regulatory approval process, our ability to fund future
research, our plans to obtain partners to assist in the further development of
our product candidates, the establishment of corporate alliances, the
Company's plans, objectives, expectations and intentions and other statements
including words such as "continue", "believe", "plan", "expect", "intend",
"will", "should", "may", and other similar expressions. Such statements
reflect our current views with respect to future events and are subject to
risks and uncertainties and are necessarily based upon a number of estimates
and assumptions that, while considered reasonable by us are inherently subject
to significant business, economic, competitive, political and social
uncertainties and contingencies. Many factors could cause our actual results,
performance or achievements to be materially different from any future
results, performance, or achievements that may be expressed or implied by such
forward-looking statements, including, among others: our ability to obtain the
capital required for research and operations, the inherent risks in early
stage drug development including demonstrating efficacy, development time/cost
and the regulatory approval process; the progress of our clinical trials; our
ability to find and enter into agreements with potential partners; our ability
to attract and retain key personnel; changing market conditions; and other
risks detailed from time-to-time in our ongoing quarterly filings, annual
information forms, annual reports and annual filings with Canadian securities
regulators and the United States Securities and Exchange Commission.
Should one or more of these risks or uncertainties materialize, or should
the assumptions set out in the section entitled "Risk Factors" in our Annual
Information Form underlying those forward-looking statements prove incorrect,
actual results may vary materially from those described herein. These
forward-looking statements are made as of the date of this press release and
we do not intend, and do not assume any obligation, to update these
forward-looking statements, except as required by law. We cannot assure you
that such statements will prove to be accurate as actual results and future
events could differ materially from those anticipated in such statements.
Investors are cautioned that forward-looking statements are not guarantees of
future performance and accordingly investors are cautioned not to put undue
reliance on forward-looking statements due to the inherent uncertainty
Lorus Therapeutics Inc.'s recent press releases are available through the
Company's website at www.lorusthera.com.
For further information:
For further information: Lorus Therapeutics Inc., Dr. Saeid Babaei,
(416) 798-1200 ext. 490, email@example.com